Pharmaceutical patents case clarifies first authorisation
Supplementary Protection Certificate appeal dismissed on reference to European case law
Pharmaceutical company Neurim appealed a decision to turn down its application for a Supplementary Protection Certificate.
The higher court dismissed the appeal, and its judgment clarifies the European definition of first authorisation of a medicinal
The rest of this document is only available to i-law.com online
If you are already a subscriber, please enter your details below to log in.